--- title: "Geron’s RYTELO Drives Revenue as Trial Risks Linger" type: "News" locale: "en" url: "https://longbridge.com/en/news/296050207.md" description: "Geron Corporation reported Q2 net revenue of $57.5 million, up 17% year-over-year, driven by strong RYTELO adoption and expanding demand. The company raised its full-year revenue guidance to the mid-to-high end of $220-$240 million. While operating expenses remained flat due to cost discipline, gross-to-net deductions increased to 20.7%, pressuring realized prices. Geron maintains a robust cash position of $327 million but faces ongoing clinical uncertainties regarding the IMpactMF trial and regulatory pricing challenges in Europe." datetime: "2026-08-17T00:27:08.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296050207.md) - [en](https://longbridge.com/en/news/296050207.md) - [zh-HK](https://longbridge.com/zh-HK/news/296050207.md) generator: "portal-rs" --- # Geron’s RYTELO Drives Revenue as Trial Risks Linger Geron Corporation ((GERN)) has held its Q2 earnings call. Read on for the main highlights of the call. ### Summer Sale - Claim 70% Off TipRanks - Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions - Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks Geron’s latest earnings call struck a broadly upbeat tone as management highlighted strong revenue growth, expanding demand for RYTELO and reinforcing scientific data in myelodysplastic syndromes and myelofibrosis. Investors also heard a message of tighter cost control and a solid cash buffer, even as management acknowledged rising gross‑to‑net pressure, cash burn and regulatory and pricing uncertainties abroad. ## Strong Net Revenue Growth Geron reported Q2 net revenue of $57.5 million, representing 17% year‑over‑year and 11% sequential growth as RYTELO adoption continues to ramp. For the first half of 2026, net revenue climbed roughly 24% versus the prior year, and management now expects to finish toward the mid‑ to high‑end of its full‑year RYTELO revenue guidance range of $220 million to $240 million. ## Demand and Account Expansion The company logged its third straight quarter of demand growth, with Q2 demand up 5% over Q1 and prescribing accounts rising 8%, extending RYTELO’s reach to about 1,575 accounts since launch. Management emphasized that first‑ and second‑line patient starts account for 34% on a rolling 12‑month basis, signaling earlier use of the drug in the treatment pathway. ## Operational Efficiency and Expense Discipline Through the first half of 2026, total operating expenses declined about 4% year‑over‑year while net revenue climbed 24%, underscoring improving operating leverage. Q2 operating expenses excluding cost of goods were $60.7 million, essentially flat versus the prior‑year quarter as higher commercial and CMC spending was offset by lower headcount‑related costs. ## Strong Balance Sheet and Cash Position Geron closed the quarter with approximately $327 million in cash, cash equivalents, restricted cash and marketable securities, giving management room to fund commercialization and clinical programs without immediate financing pressure. The company framed this cash position as providing flexibility for opportunistic innovation and strategic moves while it continues to scale RYTELO. ## Scientific Progress and Real‑World Evidence At the EHA meeting, Geron presented its first real‑world evidence study of RYTELO in lower‑risk MDS, with outcomes broadly in line with the Phase III IMerge trial, supporting confidence in the product’s performance outside controlled settings. Additional data, including an updated IMbark overall survival analysis, were cited as reinforcing the scientific rationale for IMtelestat and backing overall survival as the primary endpoint in the Phase III IMpactMF program. ## Strategic Commercial Execution and Leadership Hire Management said a refocused commercial strategy that targets high‑volume community centers, earlier patient identification and more structured omnichannel engagement is gaining traction in the field. To further sharpen business development and growth planning, Geron named Chinmaya Rath as chief business officer, a move aimed at strengthening strategic and partnering capabilities. ## Increase in Gross‑to‑Net Deductions Gross‑to‑net deductions, which capture discounts, rebates and other adjustments, climbed to 20.7% in Q2 2026 from 15.3% a year earlier, compressing the company’s realized price per unit. Management now expects gross‑to‑net to remain in the low‑ to mid‑20% range for the rest of 2026, a headwind investors will watch as it partially offsets strong topline volume growth. ## Quarterly Cash Decline Despite the sizable cash reserve, Geron’s cash and marketable securities slipped to $327 million at June 30 from $341 million at March 31, reflecting ongoing investment outflows. While management characterized the runway as strong, the quarter‑over‑quarter decline underscores that the growth story is still reliant on disciplined spending and efficient conversion of revenue into cash. ## Ongoing Investment Pressure on Spend The company continues to invest meaningfully in its pipeline and commercialization, with Q2 R&D at $22.0 million versus $21.7 million a year ago, driven largely by CMC spending, and SG&A at $38.9 million, slightly above last year on higher marketing. Total operating expenses excluding COGS remained roughly flat year‑over‑year, indicating that cost savings from headcount reductions are being redeployed into strategic initiatives rather than dropping directly to the bottom line. ## Clinical and Regulatory Uncertainty Around Interim Analysis Geron is evaluating a change to the event threshold for the interim analysis of its Phase III IMpactMF trial to stay aligned with regulators as standards evolve, particularly around overall survival endpoints. While management reiterated that the base‑case timeline for a final OS readout in the second half of 2028 remains intact, any adjustment to interim analysis parameters injects uncertainty into the prospects for earlier regulatory milestones. ## Uncertain EU Commercialization Dynamics The company’s European strategy remains in flux as management weighs the impact of MFN‑type and other evolving global pricing mechanisms on potential launches or partnerships. These dynamics could influence both the timing and economics of ex‑U.S. expansion, leaving investors without a clear line of sight on how and when Europe might contribute meaningfully to RYTELO’s revenue mix. ## Lack of Persistence and Duration Metrics Management acknowledged that it still lacks a reliable measure of therapy duration or patient persistence, limiting visibility into long‑term revenue per patient as prescribing shifts earlier in the treatment sequence. For investors, that gap complicates modeling of lifetime value and may delay clarity on how sustainable current growth trends will be as the market matures. ## Forward‑Looking Guidance and Outlook Geron reaffirmed its 2026 outlook, keeping RYTELO net product revenue guidance at $220 million to $240 million and total operating expenses at $230 million to $240 million while signaling it expects to finish toward the higher end of revenue guidance. Management also guided gross‑to‑net deductions in the low‑ to mid‑20% range, maintained inventory targets of two to four weeks and reiterated IMpactMF’s base‑case final overall survival analysis timing in the second half of 2028 as a key future catalyst. Geron’s earnings call painted the picture of a company balancing solid commercial momentum and credible scientific validation with the predictable challenges of scaling a first‑in‑class therapy. For shareholders, the key takeaways are robust revenue growth, improving operating leverage and a healthy balance sheet, set against pricing, regulatory and data‑visibility risks that will shape how durable this growth story ultimately proves. ### Related Stocks - [GERN.US](https://longbridge.com/en/quote/GERN.US.md) ## Related News & Research - [15:58 ETDid Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?](https://longbridge.com/en/news/297822926.md) - [13:36 ETKuehn Law Encourages Investors of Geron Corporation to Contact Law Firm](https://longbridge.com/en/news/297816002.md) - [Geron management to join Cantor Global Healthcare Conference fireside chat](https://longbridge.com/en/news/297782235.md) - [MBX Biosciences (MBX) Is Down 7.5% After Starting Phase 3 oPTimize Trial – Has The Bull Case Changed?](https://longbridge.com/en/news/297998759.md) - [Is Argan (AGX) A Bargain As Strong Earnings Raise Fresh Valuation Questions?](https://longbridge.com/en/news/297882822.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**